Animal tests of a potential Covid-19 vaccine being developed by Chinese researchers show it triggers an immune response against the novel coronavirus, offering some promise as it goes into early-stage human trials, according to a peer-reviewed study.
ARCoV is a messenger RNA vaccine which uses technology similar to candidates being developed by Moderna and BioNtech and Pfizer. It is the second potential Covid-19 vaccine that China's military-backed research unit has moved into clinical trials.
Results of trials of ARCoV in mice and monkeys,